Double-vine dizziness-relieving decoction for relieving Parkinson's disease and preparation method of double-vine dizziness-relieving decoction

Abstract

The invention relates to the technical field of traditional Chinese medicine preparations, in particular to a radix euonymi and caulis spatholobi dizziness relieving decoction for relieving Parkinson's disease, and the radix euonymi and caulis spatholobi dizziness relieving decoction comprises euonymus fortunei, caulis spatholobi, radix paeoniae alba, radix polygoni multiflori preparata, glossy privet fruit, radix fici simplicissimae, gastrodia elata and ramulus uncariae cum uncis. Compared with the prior art, the traditional Chinese medicine composition treats both symptoms and root causes through a multi-way synergistic effect, and has the effects of treating liver-kidney deficiency, liver-yang hyperactivity, deficiency wind internal movement and meridian stasis. The modern pharmacological basis mainly relates to the effects of calming, resisting convulsion, reducing blood pressure, improving brain circulation, promoting hematopoiesis, resisting oxidation, resisting platelet aggregation, regulating immunity, relieving spasm and the like, can be used for improving mitochondrial function damage and protein expression of mitochondrial function related protein PGC-1alpha, can be used for improving PD tyrosine hydroxylase expression and reducing abnormal aggregation of alpha-syn, and can be used for treating the mitochondrial function damage and the mitochondrial function related protein PGC-1alpha. Therefore, neurons are protected, and PD pathological conditions are improved.

Description

Technical Field

[0001] The present invention relates to the technical field of traditional Chinese medicine preparations, and in particular to a Shuangteng Xifeng decoction for alleviating Parkinson's disease and a preparation method thereof. Background Art

[0002] Parkinson's disease (PD) is caused by the gradual depletion of dopaminergic neurons in the substantia nigra pars compacta of the basal ganglia, typically accompanied by motor and non-motor signs. Motor signs include bradykinesia, resting tremor, muscle rigidity, and gait and postural balance disorders. Non-motor signs include insomnia, sensory impairment, autonomic nervous system disturbances, and psychological and cognitive impairments. These symptoms are caused by a lack of dopamine and dysfunction of the entire basal ganglia structure. Therefore, the loss of dopaminergic projections in the cortical-basal ganglia-thalamus-cortical loop is closely related to bradykinesia.

[0003] Furthermore, the globus pallidus (GP), a key component of the basal ganglia circuitry, is composed of the lateral and medial GPs in rodents and the lateral and medial globus pallidus in primates. The GP plays an important regulatory role in motor and non-motor functions. For example, depletion of dopamine levels in the GP can lead to overactivation of the cerebellothalamic circuitry, resulting in resting tremor.

[0004] Bradykinesia and resting tremor are the primary motor symptoms of Parkinson's disease (PD), characterized by slow, low-amplitude movements (hypokinesia) and a gradual decrease in speed and amplitude throughout the movement process. These symptoms are also prominent in Parkinson's mice. Dopamine-like drugs can effectively reduce protrusions and pathological beta oscillations within the GPi, improving clinical symptoms such as resting tremor in PD patients. Furthermore, levodopa is a dopamine precursor, and therefore levodopa tablets are often used clinically to treat Parkinson's disease.

[0005] However, Parkinson's disease is a typical chronic disease, and the course of the disease usually lasts for several years to decades. Taking levodopa tablets can cause gastrointestinal reactions such as nausea, vomiting, and loss of appetite, as well as mental symptoms such as insomnia, anxiety, and confusion. The characteristics of traditional Chinese medicine formulas such as warming, treating both the symptoms and the root causes, and having few side effects are more conducive to patients' treatment of chronic diseases. Summary of the Invention

[0006] The present invention aims to provide a Shuangteng Xifeng Decoction for alleviating Parkinson's disease and a preparation method thereof, aiming to solve the problems of dopaminergic neuron loss and abnormal α-syn aggregation in Parkinson's patients, and improve movement symptoms such as bradykinesia and resting tremor in patients.

[0007] To achieve the above object, the present invention provides a Shuangteng Xifeng Decoction for alleviating Parkinson's disease, wherein the Shuangteng Xifeng Decoction comprises: Fufang Caulis, Millettia reticulata, White Peony Root, Prepared Polygonum multiflorum, Ligustrum lucidum fruit, Prunus mume, Gastrodia elata and Uncaria rhynchophylla.

[0008] Preferably, in the above technical solution, the raw materials of the Shuangteng Xifeng Decoction are mainly 15-25g of Fufang Teng, 10-20g of Millettia reticulata, 10-20g of White Peony Root, 5-15g of Prepared Polygonum multiflorum, 10-20g of Gastrodia elata, 10-20g of Uncaria rhynchophylla and 10-20g of Ligustrum lucidum fruit, by weight.

[0009] Preferably, in the above technical solution, the raw materials of the Shuangteng Xifeng Decoction are mainly 18-22g of Fufang Teng, 13-17g of Millettia reticulata, 13-17g of White Peony Root, 8-12g of Prepared Polygonum multiflorum, 13-17g of Gastrodia elata, 13-17g of Uncaria rhynchophylla and 13-17g of Ligustrum lucidum fruit by weight.

[0010] Preferably, in the above technical solution, the Shuangteng Xifeng Decoction also includes Epimedium, Curcuma Atractylodes and Prunus mume.

[0011] Preferably, in the above technical scheme, the raw materials of the Shuangteng Xifeng Decoction are mainly 18-22g of Fufang Caulis, 13-17g of Millettia reticulata, 13-17g of White Peony Root, 8-12g of Epimedium, 8-12g of Prepared Polygonum multiflorum, 13-17g of Prunus mume, 8-12g of Curcuma zedoaria, 13-17g of Gastrodia elata, 13-17g of Uncaria rhynchophylla and 13-17g of Ligustrum lucidum.

[0012] Euonymus fortunei (Turcz.) Hand.-Mazz is an evergreen vine shrub of the genus Euonymus in the family Celastraceae. It is mild in nature, with a slightly bitter and sweet flavor. It nourishes the liver and kidneys, strengthens the tendons and bones, relaxes the tendons and activates the collaterals, and stops bleeding and eliminates blood stasis. In this prescription, its liver and kidney nourishing effects (promoting liver calming and extinguishing wind, relieving spasms), bone and tendon strengthening, and meridian dredging (dilating blood vessels, improving microcirculation, and inhibiting platelet aggregation) are used to treat wind-induced agitation caused by liver and kidney deficiency and meridian obstruction.

[0013] Spatholobus suberectus Dunn (Spatholobus suberectus Dunn) is the stem of the leguminous plant, Spatholobus suberectus. It is warm in nature, bitter with a slightly sweet taste. It nourishes the blood, invigorates blood circulation, and relaxes tendons and activates the collaterals. Its blood-activating and blood-tonifying properties nourish the tendons and veins, improving numbness and cramps caused by blood deficiency and blood stasis, and treating wind-induced blood deficiency or blood stasis blocking the collaterals. When used in conjunction with Eupatorium fortunei and Atractylodes lancea, it increases cerebral blood circulation, nourishes the nerves, improves underlying deficiency, enhances nerve stability, inhibits abnormal nerve activity (wind movement), and relieves dizziness, headaches, tremors, and convulsions.

[0014] Atractylodes lancea: Warm in nature, pungent and bitter in flavor. It promotes qi and resolves blood stasis, dissipates stagnation, and relieves pain. Adding blood-activating herbs to tonics relaxes tendons and unblocks meridians, preventing blockage and nerve damage. It helps treat meridian stagnation caused by deficiency-induced blood stasis or internal wind (such as vertigo, headaches, and convulsions). It increases cerebral blood circulation, relieves cramps, and improves dizziness, headaches, tremors, and convulsions caused by meridian stasis.

[0015] Fufang Teng, Millettia reticulata and Atractylodes lancea are all the main medicines, which have two tonifying effects (Fufang Teng focuses on tonifying the liver and kidneys and unblocking the meridians, Millettia reticulata focuses on tonifying blood, activating blood circulation and unblocking the meridians, and Atractylodes lancea activates blood circulation, promotes qi and prevents stagnation) and three unblocking effects, taking into account both the symptoms and the root cause, targeting the core pathogenesis of "root deficiency" (insufficient liver and kidneys, deficiency of essence and blood) and "surplus" (blocked meridians, internal movement of virtual wind).

[0016] Gastrodia elata: neutral in nature, sweet in flavor. It calms the liver and extinguishes wind, unblocks meridians, and relieves pain. It is a key herb for treating wind, particularly effective in calming the liver, extinguishing wind, and relieving dizziness. It directly targets dizziness, headache, and tremors caused by hyperactivity of liver yang and internal liver wind. It assists the main herb in extinguishing wind.

[0017] Uncaria rhynchophylla (Miq.) Miq. ex Havil., the dried, hooked stems and branches of the Rubiaceae family, are cooling in nature and sweet in flavor. They clear heat and soothe the liver, extinguish wind and stop spasms. They clear liver heat, calm liver yang, and extinguish liver wind, and are particularly effective in treating convulsions, dizziness, and headaches caused by internal liver wind. They are used in conjunction with Gastrodia elata to enhance their liver-calming and wind-extinguishing properties.

[0018] Prepared Polygonum multiflorum: Slightly warm in nature, with a bitter, sweet, and astringent flavor. It nourishes the liver and kidneys, improves essence and blood, blackens hair, and strengthens bones and tendons. It nourishes the liver and kidneys, the foundation of essence and blood. Sufficient essence and blood nourish the liver wood, preventing liver yang from rising and internal wind from forming. It assists the main herb in nourishing the liver and kidneys.

[0019] White Peony Root: Slightly cold in nature, bitter and sour in flavor. It nourishes blood and regulates menstruation, softens the liver and relieves pain, and calms liver yang. It nourishes blood and softens the liver, alleviating the liver's dry and rigid nature and calming liver yang. Together with processed Polygonum multiflorum, it helps nourish yin and blood, soften the liver and quench wind.

[0020] Ligustrum lucidum fruit: Cool in nature, sweet and bitter in flavor. Nourishes the liver and kidneys, brightens eyesight and darkens hair. It replenishes liver and kidney yin, clears away heat, and assists with the nourishment of liver and kidney yin by Polygonum multiflorum and White Peony Root. Sufficient yin can contain yang and control wind.

[0021] Gastrodia elata, Uncaria rhynchophylla, processed Polygonum multiflorum, white peony root, and Ligustrum lucidum fruit serve as assistant herbs. Gastrodia elata and Uncaria rhynchophylla directly extinguish wind and treat the symptoms, while processed Polygonum multiflorum, white peony root, and Ligustrum lucidum fruit nourish the liver and kidneys, nourishing blood and softening the liver to address the root cause. Together, these five herbs support the main herbs, strengthening the two core functions of "calming down internal wind" and "tonifying the liver and kidneys' essence and blood."

[0022] Epimedium: Warm in nature, pungent and sweet in flavor. It nourishes the kidneys and strengthens yang, strengthens bones and muscles, and relieves rheumatism. Adding a small amount of yang-warming herbs to a large number of yin-nourishing herbs (Shouwu, Ligustrum lucidum, and White Peony Root) embodies the principle of "seeking yin within yang" and "less fire generates more vitality." This allows yin to be nurtured by yang, resulting in unlimited vitality. It prevents the yin-nourishing herbs from being overly nourishing and greasy, and helps strengthen bones and muscles with the main herbs. It counteracts the cold, nourishing, and greasy properties of the yin-nourishing herbs.

[0023] Five-fingered ginseng: neutral in nature, sweet with a slightly bitter taste. It strengthens the spleen and lungs, promotes qi and eliminates dampness, and relaxes the tendons and activates the collaterals. It strengthens the spleen and replenishes qi, dissipates dampness, and unclogs the meridians. Firstly, it supports the acquired foundation (the spleen and stomach), enabling the production of qi and blood, aiding the nourishing effects of the principal and auxiliary herbs. Secondly, it relaxes the tendons and activates the collaterals, helping the principal herbs to unclog the meridians. Thirdly, its qi-promoting and dampness-eliminating properties can counteract dampness stagnation that can be caused by yin-nourishing herbs. It strengthens the spleen and aids digestion, dissipates dampness, and unclogs the meridians, harmonizing the various herbs.

[0024] Epimedium warms yang and promotes yin, balancing the cooling properties of Ligustrum lucidum and white peony root, counteracting the cold, cooling, and greasy properties of yin-nourishing herbs. Eleutherodactyl invigorates the spleen, eliminates dampness, and dredges the meridians, preventing the excessive nourishment and greasy effects of tonic herbs like Polygonum multiflorum and Ligustrum lucidum, counteracting the dampness and stagnation of these herbs, aiding absorption and ensuring the effective absorption and utilization of the formula's active ingredients, minimizing adverse reactions. These two herbs harmonize the various herbs, enhancing efficacy and reducing toxicity, assisting the monarch and minister herbs in exerting their effects from different perspectives, and eliminating or mitigating potential side effects (such as greasy, stagnation, and dampness) from other herbs in the formula, resulting in a formula that nourishes without stagnation and nourishes without greasiness.

[0025] This prescription does not explicitly list a single adjuvant. However, Uncaria rhynchophylla has the property of being light and clear and ascending, which can guide the medicinal power upward to the head and eyes, thereby better treating wind symptoms in the head and face (dizziness, headaches). The relaxing and activating effect of Osmanthus fragrans can guide the medicinal power of the monarch and minister herbs to the meridians of the limbs, thereby improving blood circulation throughout the body (especially the brain and limbs), resolving the problems of "stasis due to deficiency" or "stasis due to wind", and relieving numbness, pain, and stiffness. The overall prescription is precisely matched, and the function of harmonization is already embodied in the monarch, minister, and adjuvant herbs. Therefore, Uncaria rhynchophylla guides the medicinal power upward to the head and eyes, while Osmanthus fragrans guides the medicinal power to the meridians of the limbs, and together they guide the medicinal power to the affected area.

[0026] A method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease, the method comprising:

[0027] S1, soaking the Chinese medicinal material raw material in 900-1100 mL of water for 5-7 hours, adding 900-1100 mL of water, ultrasonically treating, and filtering to obtain a first medicinal solution and a filter residue;

[0028] S2, adding 900-1100 mL of water to the filter residue described in S1, ultrasonically treating, and filtering to obtain a second drug solution and filter residue;

[0029] S3, add water to the filter residue in S2 and repeat the previous operation, add 900-1100 mL of water, ultrasonicate, filter, obtain the third solution, and discard the filter residue;

[0030] S4, mixing the first medicinal solution, the second medicinal solution and the third medicinal solution, filtering, heating and concentrating to obtain Shuangteng Xifeng Decoction.

[0031] Preferably, in the above technical solution, the Chinese medicinal material raw materials include, by weight, 18-22g of Fufang Caulis, 13-17g of Millettia reticulata, 13-17g of White Peony Root, 8-12g of Epimedium, 8-12g of Prepared Polygonum multiflorum, 13-17g of Prunus mume, 8-12g of Curcuma zedoaria, 13-17g of Gastrodia elata, 13-17g of Uncaria rhynchophylla and 13-17g of Ligustrum lucidum fruit.

[0032] Preferably, in the above technical solution, the ultrasonic treatment process includes: ultrasonic frequency of 20-30kHz, ultrasonic intensity of 0.25-0.30W / cm 2 , the processing temperature is 80-85℃, and the processing time is 30-45min.

[0033] Preferably, in the above technical solution, the specific step of heating and concentrating comprises: heating the mixed medicinal liquid in a water bath at a temperature of 100° C., and concentrating the medicinal liquid to 200-250 mL.

[0034] Preferably, in the above technical solution, in step S4, the filtration is performed by membrane filtration, the pore size of the membrane is 800-1000 nm, and the filtration pressure is 0.2-0.4 MPa.

[0035] Compared with the prior art, the present invention has the following beneficial effects:

[0036] (1) Shuangteng Xifeng Decoction works synergistically through multiple pathways, including calming the liver and extinguishing wind, nourishing the liver and kidneys, activating blood circulation and unblocking meridians, and harmonizing medicinal properties. It treats both the symptoms and the root causes, and works together to treat liver and kidney deficiency, hyperactivity of liver yang, internal wind movement due to deficiency, and stagnation of meridians. The whole formula uses both cold and warming, tonifying and purging, and achieves proper ascending and descending effects, achieving self-harmony. Its modern pharmacological basis mainly involves sedation, anticonvulsant, antihypertensive, cerebral circulation improvement, hematopoietic promotion, antioxidant, antiplatelet aggregation, immune regulation, and antispasmodic effects.

[0037] (2) The core pharmacological effects of Shuangteng Xifeng Decoction containing Atractylodes macrocephala, Rhizoma Coptidis and Epimedium are as follows: Rhizoma Coptidis, Rhizoma Coptidis and Atractylodes macrocephala are used as the main herbs to nourish the liver and kidney, benefit the essence and blood, activate blood circulation, promote qi and dredge the meridians to treat the root deficiency and prevent the obstruction of the meridians; Gastrodia elata and Uncaria rhynchophylla are used to directly calm the liver and extinguish wind, while processed Polygonum multiflorum, Paeonia lactiflora and Fructus Ligustri Lucidi nourish the liver and kidney essence and blood, soften the liver and calm the yang to strengthen the root, and are used as the assistant herbs to strengthen the wind extinguishing and nourishing effects; Epimedium warms the yang and helps the yin, while Rhizoma Coptidis strengthens the spleen, eliminates dampness and dredges the meridians as the adjuvant herbs to harmonize the medicinal properties, eliminate side effects and enhance the efficacy of the whole prescription; Uncaria rhynchophylla and Rhizoma Coptidis have the function of guiding the meridians and making the medicines run.

[0038] (3) Shuangteng Xifeng Decoction obtained by the extraction method of the present invention can effectively upregulate the expression level of PD tyrosine hydroxylase in Parkinson's mouse models, and at the same time reduce the expression level of α-syn in Parkinson's mouse models, thereby treating and repairing mitochondrial function damage. BRIEF DESCRIPTION OF THE DRAWINGS

[0039] The purpose, features and advantages of the present invention will be further described with reference to the accompanying drawings and in conjunction with the embodiments.

[0040] Figure 1 It is a bar graph of the climbing time of each group of mice before modeling, after modeling, and after drug administration in the climbing experiment of the present invention;

[0041] Figure 2 This is a bar graph of the movement distance of each group of mice before, after and after modeling in the open field experiment of the present invention.

[0042] Figure 3 It is a bar graph of the average optical density values ​​of TH and α-syn in each group of mice in the immunohistochemistry experiment of the present invention;

[0043] Figure 4 This is the TH immunohistochemical staining diagram of each group of mice in the immunohistochemical experiment of the present invention;

[0044] Figure 5 α-syn immunohistochemical staining of each group of mice in the immunohistochemical experiment of the present invention;

[0045] Figure 6 It is a bar graph of the enzyme activity values ​​of the mitochondrial complex of each group of mice in the enzyme activity experiment of the present invention;

[0046] Figure 7 is a bar graph of cardiophospholipase activity in each group of mice in the enzyme activity experiment of the present invention;

[0047] Figure 8 It is a bar graph of protein expression of each group of mice and mitochondrial function damage in the present invention;

[0048] Figure 9 is a diagram of the original bands of PGC-1α, DRP1, and OPA1 proteins of the present invention;

[0049] Figure 10 These are the original bands of PINK1, Parkin, and α-syn proteins of the present invention. DETAILED DESCRIPTION

[0050] The technical solutions in the embodiments of the present invention are clearly and completely described. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. All other embodiments obtained by ordinary technicians in this field based on the embodiments of the present invention without making any creative efforts shall fall within the scope of protection of the present invention.

[0051] Example 1

[0052] A Shuangteng Xifeng Decoction for relieving Parkinson's disease. The raw materials of the Shuangteng Xifeng Decoction are mainly 20g of Fufang Caulis, 15g of Millettia reticulata, 15g of White Peony Root, 10g of Epimedium, 10g of Prepared Polygonum multiflorum, 15g of Prunus mume, 10g of Atractylodes macrocephala, 15g of Gastrodia elata, 15g of Uncaria rhynchophylla and 15g of Ligustrum lucidum fruit.

[0053] A method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease, the method comprising:

[0054] S1, soak Chinese medicinal materials (20g of Eucommia ulmoides, 15g of Millettia reticulata, 15g of White Peony Root, 10g of Epimedium, 10g of Prepared Polygonum Multiflorum, 15g of Trichosanthes kirilowii, 10g of Rhizoma Coptidis, 15g of Rhizoma Gastrodiae, 15g of Uncaria rhynchophylla, and 15g of Fructus Ligustri Lucidi) in 1000mL of water for 5-7 hours, add 1000mL of water, perform ultrasonic treatment, and filter to obtain a first medicinal solution and a filter residue. The ultrasonic treatment process is as follows: the ultrasonic frequency is 25kHz, the ultrasonic intensity is 0.28W / cm 2 , the treatment temperature is 80℃ and the treatment time is 45min;

[0055] S2, adding 1000 mL of water to the filter residue in S1, ultrasonically treating, and filtering to obtain a second liquid and filter residue, wherein the ultrasonic treatment process is the same as S1;

[0056] S3, adding water to the filter residue in S2 and repeating the previous operation, adding 1000 mL of water, ultrasonically treating, filtering, obtaining a third liquid, and discarding the filter residue, wherein the ultrasonic treatment process is the same as S1;

[0057] S4, mix the first medicinal liquid, the second medicinal liquid and the third medicinal liquid, filter with a filter membrane pore size of 8 μm and a filtration pressure of 0.3 MPa, place the mixed medicinal liquid in a water bath at a temperature of 100°C and concentrate it to 200 mL of medicinal liquid to obtain Shuangteng Xifeng Decoction, the crude drug concentration of the Shuangteng Xifeng Decoction is 1.3 g / mL, and store it in a refrigerator at 4°C for use.

[0058] Example 2

[0059] A Shuangteng Xifeng Decoction for relieving Parkinson's disease. The raw materials of the Shuangteng Xifeng Decoction are mainly 20g of Fufang Teng, 15g of Millettia reticulata, 15g of White Peony Root, 10g of Prepared Polygonum multiflorum, 15g of Gastrodia elata, 15g of Uncaria rhynchophylla and 15g of Ligustrum lucidum fruit, calculated by weight.

[0060] A method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease, the method comprising:

[0061] S1, soak Chinese medicinal materials (20g of Euonymus fortunei, 15g of Millettia reticulata, 15g of White Peony Root, 10g of Polygonum multiflorum processed, 15g of Gastrodia elata, 15g of Uncaria rhynchophylla, and 15g of Ligustrum lucidum fruit) in 1000mL of water for 5-7 hours, then add 1000mL of water, ultrasonically treat, and filter to obtain a first medicinal liquid and a filter residue. The ultrasonic treatment process is as follows: the ultrasonic frequency is 25kHz, the ultrasonic intensity is 0.28W / cm 2 , the treatment temperature is 80℃ and the treatment time is 45min;

[0062] S2, adding 1000 mL of water to the filter residue in S1, ultrasonically treating, and filtering to obtain a second liquid and filter residue, wherein the ultrasonic treatment process is the same as S1;

[0063] S3, adding water to the filter residue in S2 and repeating the previous operation, adding 1000 mL of water, ultrasonically treating, filtering, obtaining a third liquid, and discarding the filter residue, wherein the ultrasonic treatment process is the same as S1;

[0064] S4, mix the first medicinal liquid, the second medicinal liquid and the third medicinal liquid, filter with a filter membrane pore size of 8 μm and a filtration pressure of 0.3 MPa, place the mixed medicinal liquid in a water bath at a temperature of 100°C and concentrate it to 200 mL of medicinal liquid to obtain Shuangteng Xifeng Decoction, the crude drug concentration of the Shuangteng Xifeng Decoction is 1.3 g / mL, and store it in a refrigerator at 4°C for use.

[0065] Example 3

[0066] A Shuangteng Xifeng Decoction for relieving Parkinson's disease. The raw materials of the Shuangteng Xifeng Decoction are mainly 18g of Fufang Caulis, 17g of Millettia reticulata, 17g of White Peony Root, 12g of Epimedium, 12g of Prepared Polygonum Multiflorum, 17g of Prunus mume, 12g of Atractylodes macrocephala, 17g of Gastrodia elata, 17g of Uncaria rhynchophylla and 17g of Ligustrum lucidum fruit.

[0067] 1. Establishment of PD Mouse Model

[0068] Parkinson's disease (PD) is the most common movement disorder, associated with both motor and non-motor signs. Among them, 6-hydroxydopamine (6-OHDA), 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP), rotenone, and paraquat are the most widely used neurotoxic drugs in clinical practice. MPTP is one of the most commonly used neurotoxins in PD animal models. MPTP is a small, lipid-soluble molecule that readily crosses the blood-brain barrier. Following drug administration, monoamine oxidase B converts MPTP into 1-methyl-4-phenylpyridinium ion (MPP+), which is toxic to DA neurons. MPP+ is a toxic substance similar to DA and is directly taken up by DA neurons. Its mechanism of action is through MPP+'s inhibition of mitochondrial respiratory complex I. Studies have found that adenine triphosphate (ATP) levels decrease significantly in the substantia nigra and striatum, leading to apoptosis and subsequent death of DA neurons. The MPTP animal model has unique antagonism in mitochondria and is of great significance for studying the occurrence and development of Parkinson's disease. In order to achieve a high degree of simulation of Parkinson's disease in mice, long-term injection of MPTP drugs must be insisted on to achieve the accumulation of toxins in the mouse body. MPTP has higher neurotoxicity to C57 mice. Their clinical symptoms, pathology and biochemistry are similar to those of Parkinson's patients, and they are in a relatively stable state. It is the best model for studying Parkinson's disease. Therefore, we used MPTP as the main modeling reagent to establish a subacute Parkinson's disease animal model. The subacute Parkinson's disease (PD) animal model is characterized by neuronal damage. This model is relatively simple, safe, and has a high animal survival rate. It is consistent with our research goals and is more suitable for this experiment.

[0069] Experimental subjects: Male clean-grade C57 mice;

[0070] Modeling method: 1g of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine hydrochloride (MPTP) was injected intraperitoneally into C57 mice. Symptoms such as limb tremor, decreased motor function, and hunched back stiffness appeared within minutes to hours. MPTP was continuously injected intraperitoneally for 7 days. The C57 mice were then housed normally. If the mice still maintained these symptoms after 7 days, the PD mouse model was successfully established. A blank control group was not given any modeling drugs.

[0071] The MPTP is Puxitang brand, batch number is M60002

[0072] During the process of preparing the subacute Parkinson's disease animal model by intraperitoneal injection of the MPTP reagent, there was no death or shedding of C57 mice.

[0073] 2. Dosage Method

[0074] In Example 1 group, PD mice were fed with Shuangteng Xifeng Decoction prepared in Example 1;

[0075] In Example 2, PD mice were fed with Shuangteng Xifeng Decoction prepared in Example 2;

[0076] In the Western medicine group, PD mice were fed with levodopa tablets (0.25 g / tablet) purchased from Shanghai Fuda Pharmaceutical Co., Ltd. (Batch No.: D0506);

[0077] The model group and the blank group were not fed with any drugs.

[0078] 3. Pole climbing experiment

[0079] The pole climbing time of PD mice treated with different drug administration methods before modeling, after modeling and after drug administration is shown in Table 1.

[0080] Table 1 Effects of different drug administration methods on the climbing time of PD model mice

[0081]

[0082]

[0083] Note: After modeling: ** indicates P < 0.01 compared with the blank group; after drug administration: ** indicates P < 0.01 compared with the blank group; ## indicates P < 0.01 compared with the model group.

[0084] Figure 1 As shown in Table 1, before modeling, there was no significant difference in the pole climbing time of each group (P>0.05); after modeling, compared with the blank group, the pole climbing time of the four groups of PD mice was significantly prolonged (P<0.01); compared with the model group, there was no significant difference in the pole climbing time of the western medicine group and Example 1 group and Example 2 group (P>0.05), indicating that the modeling of mice in the western medicine group, Example 1 group and Example 2 group was successful.

[0085] Furthermore, after drug treatment, compared with the blank group, the pole climbing time of the model group was prolonged, with significant differences, indicating that the mice in the model group without drug administration had significantly poorer pole climbing ability; compared with the blank group, there was no significant difference in the pole climbing time of the Example 2 group, the Western medicine group and the Example 1 group, indicating that the exercise ability of the PD mice after drug administration was not much different from that of the blank group mice; compared with the model group, the pole climbing time of the Example 1 group, the Example 2 group and the Western medicine group was significantly shortened, with extremely significant differences, indicating that the Chinese medicinal ingredients in the Example 1 group and the Example 2 group had similar effects on improving the exercise ability of PD mice as the Western medicine group, and both had good improvement effects.

[0086] 4. Open field experiment

[0087] The movement distances of PD mice treated with different drug administration methods before modeling, after modeling and after drug administration are shown in Table 2.

[0088] Table 2 Effects of different drug administration methods on the movement distance of PD model mice

[0089] Group Number Before modeling After modeling After administration Blank group 8 2223.39±386.93 2239.15±122.58 1754.91±376.94 Model Group 8 1977.89±256.29 <![CDATA[655.29±216.56 * ]]> <![CDATA[659.96±196.23 ** ]]> Example 1 group 8 2130.81±307.42 <![CDATA[928.18±222.61 *# ]]> <![CDATA[1884.38±455.82 ## ]]> Example 2 group 8 2242.52±422.76 <![CDATA[826.98±314.77 * ]]> <![CDATA[1248.32±375.72 **## ]]> Western medicine group 8 2040.52±192.41 <![CDATA[859.59±119.92 * ]]> <![CDATA[1394.05±463.23 ## ]]>

[0090] Note: After modeling: * indicates P < 0.01 compared with the blank group; # indicates P < 0.05 compared with the model group; After drug administration: ** indicates P < 0.01 compared with the blank group; ## indicates P < 0.01 compared with the model group.

[0091] like Figure 2 As shown in Table 2, in terms of movement distance, before modeling, there was no significant difference in the movement distance of each group (P>0.05); after successful modeling, compared with the blank group, the movement distance of the 4 groups of PD mice was significantly reduced (P<0.01); compared with the model group, the movement distance of the PD mice in Example 1 group was slightly increased, which was different (P<0.05); there was no significant difference in the movement distance of the Western medicine group and Example 2 group (P>0.05). After drug treatment, compared with the blank group, the movement distance of the model group and Example 2 group was shortened, which was different (P<0.05). There was no significant difference between the western medicine group and the Example 1 group (P>0.05); compared with the model group, the movement distance of the Example 1 group, the Example 2 group, and the western medicine group was significantly increased, indicating that the administration of Chinese and Western medicines improved the movement distance of PD mice to a certain extent, among which the movement distance of the mice in the Example 1 group was farther than that in the Example 2 group, indicating that adding Epimedium, Curcuma zedoaria, and Fructus cinnamomi to the traditional Chinese medicine formula can better improve the exercise ability of PD mice.

[0092] 5. Immunohistochemistry

[0093] Image J software was used to analyze the optical density of immunohistochemical photos. Three 200-fold photos were selected for each section, and their average optical density was calculated for comparative analysis. The average optical density values ​​of TH and α-syn in each group are shown in Table 3 and Figure 3 As shown in Figure 2, the TH immunohistochemical staining of each group is shown in Figure 2. Figure 4 As shown, α-syn immunohistochemical staining is shown in Figure 5 shown.

[0094] Table 3 Average optical density of TH and α-syn in each group

[0095] Group TH α-syn Blank group 0.088±0.013 0.017±0.012 Model Group <![CDATA[0.026±0.007 ** ]]> <![CDATA[0.040±0.005 ** ]]> Example 1 group <![CDATA[0.089±0.011 ## ]]> <![CDATA[0.012±0.003 ## ]]> Example 2 group 0.035±0.013 <![CDATA[0.015±0.003 ## ]]> Western medicine group <![CDATA[0.086±0.009 ## ]]> <![CDATA[0.013±0.006 ## ]]>

[0096] Note: ** indicates P < 0.01 compared with the blank group; ## indicates P < 0.05 compared with the model group.

[0097] The core pathological features of Parkinson's disease (PD) are the progressive and specific loss of dopaminergic neurons in the substantia nigra pars compacta (SNpc) of the midbrain, as well as the abnormal aggregation of α-synuclein (α-syn). Abnormal aggregation of α-syn reduces the clearance of autophagosomes, impairing autophagy in DA neurons, leading to neuronal death. Consequently, these pathological changes lead to neurotransmitter deficiency in dopamine projection targets such as the dorsal striatum, which in turn triggers motor dysfunction (such as bradykinesia, muscle rigidity, and resting tremor), accompanied by the emergence of non-motor symptoms such as depression and sleep disorders. Therefore, inhibiting the excessive accumulation of α-syn and protecting neuronal autophagy may be important ways to slow or prevent the pathological conditions of PD.

[0098] From Table 3 and Figure 3 As shown, compared with the blank group, the TH positive expression in the substantia nigra of the mice in the model group was significantly reduced (P < 0.01), and the α-syn positive expression in the model group was significantly increased (P < 0.01). Compared with the model group, the TH positive expression in the substantia nigra of the mice in the Example 1 group and the Western medicine group was significantly increased (P < 0.01), and the α-syn positive expression in the substantia nigra of the mice in the Example 1 group, the Example 2 group, and the Western medicine group was significantly reduced (P < 0.01), indicating that the combined use of Fufang Caulis, Millettia Spatholobi, White Peony Root, Epimedium, Preparatos Multiflori, Five-fingered Hair Peach, Curcuma Atractylodes, Gastrodia elata, Uncaria rhynchophylla and Ligustrum lucidum has a significant effect on the TH and α-syn positive expression in the substantia nigra of mice, and the compound is more significant than the compound of Fufang Caulis, Millettia Spatholobi, White Peony Root, Preparatos Multiflori, Gastrodia elata, Uncaria rhynchophylla and Ligustrum lucidum in inhibiting the excessive accumulation of α-syn and protecting the neuronal autophagy function.

[0099] Furthermore, the positive expression of α-syn in the mice in the Example 1 group was significantly reduced, and the positive expression of TH was significantly increased. This shows that the components and ratios of Shuangteng Xifeng Decoction in Example 1 can effectively increase the expression level of tyrosine hydroxylase (TH) in the Parkinson's mouse model, while reducing the expression level of α-syn in the Parkinson's mouse model, thereby achieving a neuroprotective effect. It can be further inferred that the use of ultrasonic treatment to extract the active ingredients in Shuangteng Xifeng Decoction is correlated with the expression of TH and α-syn in the substantia nigra of the mouse midbrain, indicating that this preparation method can obtain Shuangteng Xifeng Decoction with significant therapeutic effects on Parkinson's mice.

[0100] 6. Enzyme activity detection

[0101] The ingested MPTP interferes with the electron transfer chain (ETC) in the cell and generates the highly toxic 1-methyl-4-phenylpyridine (MPP) through enzyme catalysis. + ), MPP+ can cause oxidative stress (such as nitric oxide) and ATP production is blocked, resulting in intracellular Ca 2+Increased levels of oxidative stress can cause excitotoxicity and subsequently lead to neuronal damage. Therefore, oxidative stress is closely related to the development and progression of PD, and mitochondrial damage is a representative form of oxidative stress. To understand the relationship between mitochondrial damage and the development and progression of PD, enzyme activity in each group of mice was tested. The results are shown in Tables 4 and 5.

[0102] Table 4 Status of mitochondrial complex I-III in each group

[0103] Group Mitochondrial complex I Mitochondrial complex II Mitochondrial complex III Blank group 222.53±38.47 63.91±4.45 30.94±3.66 Model Group <![CDATA[77.24±15.61 ## ]]> <![CDATA[31.39±2.92 ## ]]> <![CDATA[15.31±6.54 ## ]]> Example 1 group <![CDATA[271.55±15.44 ** ]]> <![CDATA[66.94±2.03 ** ]]> <![CDATA[33.03±1.88 ** ]]> Example 2 group <![CDATA[210.27±49.29 ** ]]> <![CDATA[59.83±3.86 ** ]]> <![CDATA[27.19±4.41 * ]]> Western medicine group <![CDATA[206.78±12.34 ** ]]> <![CDATA[58.71±2.08 ** ]]> <![CDATA[26.29±1.21 ** ]]>

[0104] Note: Compared with the blank group, ## indicates P < 0.01; compared with the model group, ** indicates P < 0.01; * indicates P < 0.05.

[0105] Table 5 Mitochondrial complex IV and cardiolipin status in each group

[0106] Group Mitochondrial complex IV Cardiolipin Blank group 38.01±6.08 0.52±0.62 Model Group <![CDATA[19.89±5.97 ## ]]> <![CDATA[0.21±0.02 ## ]]> Example 1 group <![CDATA[43.51±3.95 ** ]]> <![CDATA[0.52±0.01 ** ]]> Example 2 group <![CDATA[28.66±1.61 ** ]]> <![CDATA[0.46±0.12 ** ]]> Western medicine group <![CDATA[36.59±1.69 ** ]]> <![CDATA[0.54±0.05 ** ]]>

[0107] Note: Compared with the blank group, ## indicates P < 0.01; compared with the model group, ** indicates P < 0.01; * indicates P < 0.05.

[0108] From Table 4-5 and Figure 6-7 It was found that the enzyme activities of mitochondrial complexes I, II, III, and IV of mice in the model group were all lower than those in the blank group. Therefore, it can be concluded that mitochondrial damage is closely related to PD. The enzyme activities of mitochondrial complexes and cardiolipin in the Example 1 group were similar to those in the Western medicine group and the blank group. Therefore, the Shuangteng Xifeng Decoction and Western medicine team in the Example 1 and Example 2 groups had significant therapeutic effects in treating and repairing mitochondrial functional damage, maintaining the normal function of mitochondria, and reducing oxidative stress caused by mitochondrial functional damage and causing less neuronal damage. Furthermore, the Example 1 group had better efficacy in treating and repairing mitochondrial functional damage than the Example 2 group, indicating that adding Atractylodes macrocephala, Epimedium brevicornum, Radix Gastrodiae, Rhizoma Uncariae, and Fructus Ligustri Lucidi to the herbs of Atractylodes macrocephala, Epimedium brevicornum, and Fructus Ligustri Lucidi can better treat and repair mitochondrial functional damage.

[0109] VII. Western blot analysis of mitochondrial dysfunction-related protein expression

[0110] Mitochondrial dysfunction causes neuronal damage, so repairing mitochondrial dysfunction is the key to protecting neurons and slowing or preventing the progression of PD pathology. To further explore the effects of different drug administration methods on the expression of mitochondrial dysfunction-related proteins.

[0111] Table 6 PGC-1a, DRP1, and OPA1 protein expression in each group

[0112] Group PGC-1a DRP1 OPA1 Blank group <![CDATA[1.91±0.71 ** ]]> <![CDATA[1.64±0.41 ** ]]> <![CDATA[0.83±0.28 ** ]]> Model Group <![CDATA[0.31±0.07 ## ]]> 2.40±0.44 <![CDATA[2.43±0.32 ## ]]> Example 1 group <![CDATA[2.15±0.55 ** ]]> <![CDATA[1.47±0.43 ** ]]> <![CDATA[0.78±0.46 ** ]]> Example 2 group <![CDATA[1.77±0.44 ** ]]> 1.78±0.59 <![CDATA[1.17±0.36 ** <!-- 8 -->]]> Western medicine group <![CDATA[1.89±0.67 ** ]]> <![CDATA[1.27±0.51 ** ]]> <![CDATA[0.94±0.57 ** ]]>

[0113] Note: Compared with the blank group, ## indicates P < 0.05; # indicates P < 0.01; compared with the model group, ** indicates P < 0.05; & indicates P < 0.01 (n = 3).

[0114] Table 7 Expression of PINK1, Parkin and α-syn proteins in each group

[0115] Group PINK1 Parkin α-syn Blank group <![CDATA[1.60±0.73 ** ]]> <![CDATA[1.33±0.33 ** ]]> <![CDATA[1.21±0.26 & ]]> Model Group 2.53±0.39 <![CDATA[2.61±0.31 ## ]]> <![CDATA[2.80±0.35 # ]]> Example 1 group <![CDATA[0.98±0.46 ** ]]> <![CDATA[1.03±0.79 ** ]]> <![CDATA[0.98±0.66 & ]]> Example 2 group <![CDATA[1.15±0.55 ** ]]> <![CDATA[1.39±0.57 ** ]]> <![CDATA[1.22±0.41 ** ]]> Western medicine group <![CDATA[1.07±0.25 ** ]]> <![CDATA[1.10±0.75 ** ]]> <![CDATA[1.01±0.45 & ]]>

[0116] Note: Compared with the blank group, ## indicates P < 0.05; # indicates P < 0.01; compared with the model group, ** indicates P < 0.05; & indicates P < 0.01 (n = 3).

[0117] From Table 6-7 and Figure 8 It can be seen that compared with the blank group, the expression of PGC-1α protein in the model group was significantly downregulated (P < 0.05), while the expression levels of OPA1 and Parkin proteins were increased (P < 0.05); the expression of α-syn protein was significantly increased (P < 0.01); although the expression of DRP1 and PINK1 proteins showed an increasing trend, there was no statistical difference (P > 0.05). Compared with the model group, the expression of PGC-1α in Example 1 group was significantly better than that in Example 2 group and the Western medicine group (P < 0.05). Compared with the model group, the expression of DRP1 protein in Example 1 group and the Western medicine group was significantly reduced (P < 0.05), and although there was a downward trend in Example 2 group, it was not statistically significant (P > 0.05). Compared with the model group, significant inhibition of OPA1, PINK1, and Parkin protein expression was observed in all treatment groups (Example 1, Example 2, and Western medicine) (P < 0.05), among which the expression of Parkin protein in Example 1 group reached the lowest level. Compared with the model group, the expression of α-syn protein in Example 1 group and the Western medicine group was significantly reduced (P < 0.01), and the Example 2 group also showed statistical differences (P < 0.05), but the decrease was smaller, indicating that the Chinese medicinal materials in Example 2 group have the effect of increasing PGC-1α protein expression and inhibiting DRP1, OPA1, PINK1, Parkin, and α-syn protein expression.

[0118] from Figure 9 It can be seen that the PGC-1α protein expression level in the model group was lower than that in the Example 1 group and the Western medicine group; the DRP1 and OPA1 protein expression levels in the model group were higher than those in the Example 1 group and the Western medicine group.

[0119] from Figure 10 It can be seen that the expression levels of PINK1, Parkin, and α-syn proteins in the model group were higher than those in the Example 1 group and the Western medicine group.

[0120] From Table 4-5 and Figure 7-8WB was used to detect the expression of proteins related to mitochondrial dysfunction. The results showed that the expression of PGC-1α protein in the model group was low, and the expression of OPA1, PINK1 and α-syn proteins in the model group was higher, with statistical differences. The DRP1 and PINK1 proteins in the model group were increased to varying degrees, but the differences were not statistically significant. The difference was not statistically significant because the sample size was small, but the data showed a trend of difference, so it could reflect to a certain extent that the mitochondrial function of the model group had been impaired. By comparing the three groups of Western medicine group, Example 2 group and Example 1 group with the model group, it was found that the expression of PGC-1α protein in the three groups was increased, and the expression of PGC-1α protein in Example 1 group was significantly higher than that in Example 2 group and Western medicine group. At the same time, the expression of OPA1, PINK1 and α-syn proteins in the three groups was significantly reduced.

[0121] Example 4

[0122] A Shuangteng Xifeng Decoction for relieving Parkinson's disease. The raw materials of the Shuangteng Xifeng Decoction are mainly 20g of Fufang Caulis, 15g of Millettia reticulata, 15g of White Peony Root, 10g of Epimedium, 10g of Prepared Polygonum multiflorum, 15g of Prunus mume, 10g of Atractylodes macrocephala, 15g of Gastrodia elata, 15g of Uncaria rhynchophylla and 15g of Ligustrum lucidum fruit.

[0123] A method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease, the method comprising:

[0124] S1, soak the Chinese medicinal materials (20g of Euonymus fortunei, 15g of Millettia reticulata, 15g of White Peony Root, 10g of Epimedium, 10g of Polygonum multiflorum (prepared), 15g of Trichosanthes kirilowii, 10g of Curcuma lappa, 15g of Gastrodia elata, 15g of Uncaria rhynchophylla, and 15g of Ligustrum lucidum fruit) in 1000mL of water for 5-7 hours, add another 1000mL of water, boil over high heat, then reduce to low heat and boil until the volume is reduced to 250mL, filter, and obtain the first medicinal liquid and filter residue;

[0125] S2, taking the filter residue from step S1, adding 700 mL of water and boiling over high heat, then reducing the heat to low and boiling until 250 mL is left, to obtain a second medicinal solution and filter residue;

[0126] S3, mixing the first medicinal liquid and the second medicinal liquid to obtain Shuangteng Xifeng Decoction.

[0127] The content of dulcitol in Shuangteng Xifeng Decoction of Example 1 and Example 4 (Table 8) was determined under the following chromatographic conditions: chromatographic column: Agilent 5HC-C18250*4.6mm; mobile phase: acetonitrile-water (90:10); flow rate: 1.0 ml / min; column temperature: 28°C.

[0128] Table 8 Dulcitol content in Example 1 and Example 4 groups

[0129] Group Dulcitol content (mg / g) Example 1 group 1.327 Example 4 Group 1.114

[0130] The content of dulcitol in Shuangteng Xifeng Decoction prepared using the preparation method of Example 1 is 1.327 mg / g, while the content of dulcitol in Shuangteng Xifeng Decoction prepared using the preparation method of Example 4 is 1.114 mg / g, indicating that the preparation method of Example 1 is better for extracting the effective ingredients of Chinese medicinal materials.

[0131] The present invention can be implemented in various ways and is not limited to the embodiments described above. A person skilled in the art will appreciate that the present invention can be implemented in other specific ways without changing the technical concept or essential features of the present invention. Therefore, it should be understood that the embodiments described above are illustrative and not intended to limit the present invention.

Claims

1. A Shuangteng Xifeng Decoction for alleviating Parkinson's disease, characterized in that: The raw materials of Shuangteng Xifeng Decoction are mainly Fufang Caulis, Millettia reticulata, White Peony Root, Prepared Polygonum multiflorum, Ligustrum lucidum fruit, Trichosanthes kirilowii, Gastrodia elata and Uncaria rhynchophylla.

2. The Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 1, characterized in that: By weight, the raw materials of the Shuangteng Xifeng Decoction are mainly 15-25g of Fufang Teng, 10-20g of Millettia reticulata, 10-20g of White Peony Root, 5-15g of Prepared Polygonum multiflorum, 10-20g of Gastrodia elata, 10-20g of Uncaria rhynchophylla and 10-20g of Ligustrum lucidum fruit.

3. The Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 2, characterized in that: By weight, the raw materials of the Shuangteng Xifeng Decoction are mainly 18-22g of Fufang Teng, 13-17g of Millettia reticulata, 13-17g of White Peony Root, 8-12g of Prepared Polygonum multiflorum, 13-17g of Gastrodia elata, 13-17g of Uncaria rhynchophylla and 13-17g of Ligustrum lucidum fruit.

4. The Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 3, characterized in that: The Shuangteng Xifeng Decoction also includes Epimedium, Atractylodes macrocephala and Prunus mume.

5. The Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 4, characterized in that: By weight, the raw materials of the Shuangteng Xifeng Decoction are mainly 18-22g of Fufang Caulis, 13-17g of Millettia reticulata, 13-17g of White Peony Root, 8-12g of Epimedium, 8-12g of Prepared Polygonum multiflorum, 13-17g of Prunus mume, 8-12g of Curcuma zedoaria, 13-17g of Gastrodia elata, 13-17g of Uncaria rhynchophylla and 13-17g of Ligustrum lucidum fruit.

6. A method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease, characterized in that: The preparation method comprises: S1, soaking the Chinese medicinal material raw material in 900-1100 mL of water for 5-7 hours, adding 900-1100 mL of water, ultrasonically treating, and filtering to obtain a first medicinal solution and a filter residue; S2, adding 900-1100 mL of water to the filter residue described in S1, ultrasonically treating, and filtering to obtain a second drug solution and filter residue; S3, add water to the filter residue in S2 and repeat the previous operation, add 900-1100 mL of water, ultrasonicate, filter, obtain the third solution, and discard the filter residue; S4, mixing the first medicinal solution, the second medicinal solution and the third medicinal solution, filtering, heating and concentrating to obtain Shuangteng Xifeng Decoction.

7. The method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 6, characterized in that: By weight, the Chinese medicinal materials include 18-22g of Eucommia ulmoides, 13-17g of Millettia reticulata, 13-17g of White Peony Root, 8-12g of Epimedium, 8-12g of Prepared Polygonum multiflorum, 13-17g of Trichosanthes kirilowii, 8-12g of Curcuma zedoaria, 13-17g of Gastrodia elata, 13-17g of Uncaria rhynchophylla and 13-17g of Ligustrum lucidum fruit.

8. The method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 6, characterized in that: The ultrasonic treatment process includes: ultrasonic frequency of 20-30kHz, ultrasonic intensity of 0.25-0.30W / cm 2 , the processing temperature is 80-85℃, and the processing time is 30-45min.

9. The method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 6, characterized in that: The specific steps of heating and concentrating include: heating the mixed medicinal liquid in a water bath at a water bath temperature of 100° C., and concentrating the medicinal liquid to 200-250 mL.

10. The method for preparing Shuangteng Xifeng Decoction for alleviating Parkinson's disease according to claim 6, characterized in that: In step S4, the filtration is performed by microfiltration, the pore size of the filter membrane is 5-10 μm, and the filtration pressure is 0.2-0.4 MPa.

Images